Home / Investors / Overview

Company Information

CymaBay Therapeutics (NASDAQ: CBAY)

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800

Recent News


CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017


CymaBay Therapeutics to Present at Two Investor Conferences in April


CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.

Q4 2016 Quarterly Results

Overview Overview